For how we live.
Every article we have published on Continuous Glucose Monitoring, newest first.
In 143 people with poorly controlled type 1 diabetes, a system that prompts injections through glucose-sensor alerts was non-inferior to standard monitoring — and acting on the alerts drove the benefit.
A single-centre study used continuous glucose monitoring to fine-tune insulin in people fed intravenously overnight. Time-in-range and weight improved — but with 12 patients and no control group, it is proof of concept.
Since 2024 the FDA has cleared over-the-counter CGMs for people who don't use insulin. The first independent accuracy check in adults without diabetes finds the sensors track the trend but miss the exact number.
A closed-loop system links a glucose sensor to an insulin pump so software doses automatically. In the pivotal 6-month trial it raised time in target range by 11 points over a standard pump — a bounded gain, not a cure.
Saving starch for the end of a meal reliably blunts the glucose rise afterwards in small trials — but the evidence is short-term, low-certainty, and silent on whether it changes long-term control.
Emulating a trial inside Veterans Health Administration records, researchers estimated adjusted mortality risk ratios of 0.90 to 0.84 for starting continuous glucose monitoring in older-onset type 1 diabetes.
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.